Maxwell v. Sanofi US Services Inc. et al

Plaintiff Reponza Maxwell used the chemotherapy drug Taxotere from May to July 2010 to treat breast cancer. By December 2010, she experienced permanent hair loss and thinning, which she attributed to Taxotere. Nearly seven years later, in 2017, she filed a complaint against manufacturers Sanofi-Aventis U.S. LLC and Sanofi US Services Inc., alleging that her permanent hair loss was a side effect of the drug. The case was remanded from multidistrict litigation In re: Taxotere (Docetaxel) Products Liability Litigation. Defendants moved for judgment on the pleadings, arguing that Maxwell's claims were time-barred. The U.S. District Court for the Northern District of Alabama granted the motion and dismissed the action with prejudice on October 27, 2023.

The court granted Defendants' motion for judgment on the pleadings and dismissed the action with prejudice, holding that Maxwell's claims were time-barred because her injury accrued in December 2010 and she did not file her complaint until 2017, exceeding the two-year statute of limitations under Alabama law.

Whether Maxwell's product liability claims were barred by Alabama's two-year statute of limitations. The court examined whether her injury accrued in December 2010 when she experienced permanent hair loss, or at a later date. Maxwell argued for fraudulent concealment tolling under Alabama Code § 6-2-3 and equitable tolling, but the court found her fraud claims lacked particularity and that publicly available information about Taxotere's link to permanent hair loss could have been discovered through reasonable diligence.

The ruling underscores the strict application of statutes of limitations in pharmaceutical product liability cases, even where plaintiffs allege latent injuries. It highlights the importance of timely filing and the high bar for invoking fraudulent concealment or equitable tolling doctrines. The decision may discourage delayed claims in the broader Taxotere multidistrict litigation and reinforce the need for plaintiffs to act promptly upon discovering potential injuries.